| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From Oregon Health & Science University (Drs. Nutt and Burchiel), Portland; Rush Presbyterian St. Luke’s Medical Center (Drs. Comella and Penn), Chicago, IL; Baylor College of Medicine (Drs. Jankovic and Simpson), Houston, TX; Toronto Western Hospital (Drs. Lang and Lozano), Canada; Department of Neurology (Drs. Laws and Wooten), University of Virginia Health Sciences Center, Charlottesville; and Barrows Neurological Institute (Dr. Stacy), Phoenix, AZ.
Address correspondence and reprint requests to Dr. J.G. Nutt, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, OP32, Portland, OR 97201-3098; e-mail: nuttj{at}ohsu.edu
Objective: To assess the safety, tolerability, and biological activity of glial cell line-derived neurotrophic factor (GDNF) administered by an implanted intracerebroventricular (ICV) catheter and access port in advanced PD.
Background: GDNF is a peptide that promotes survival of dopamine neurons. It improved 6-OHDA- or MPTP-induced behavioral deficits in rodents and monkeys.
Methods: A multicenter, randomized, double-blind, placebo-controlled, sequential cohort study compared the effects of monthly ICV administration of placebo and 25, 75, 150, 300, and 500 to 4,000 µg of GDNF in 50 subjects with PD for 8 months. An open-label study extended exposure up to an additional 20 months and maximum single doses of up to 4,000 µg in 16 subjects. Laboratory testing, adverse events (AE), and Unified Parkinson’s Disease Rating Scale (UPDRS) scoring were obtained at 1- to 4-week intervals throughout the studies.
Results: Twelve subjects received placebo and seven or eight subjects were assigned to each of the other GDNF dose groups. "On" and "off" total and motor UPDRS scores were not improved by GDNF at any dose. Nausea, anorexia, and vomiting were common hours to several days after injections of GDNF. Weight loss occurred in the majority of subjects receiving 75 µg or larger doses of GDNF. Paresthesias, often described as electric shocks (Lhermitte sign), were common in GDNF-treated subjects, were not dose related, and resolved on discontinuation of GDNF. Asymptomatic hyponatremia occurred in over half of subjects receiving 75 µg or larger doses of GDNF; it was symptomatic in several subjects. The open-label extension study had similar AE and lack of therapeutic efficacy.
Conclusions: GDNF administered by ICV injection is biologically active as evidenced by the spectrum of AE encountered in this study. GDNF did not improve parkinsonism, possibly because GDNF did not reach the target tissues—putamen and substantia nigra.
This article has been cited by other articles:
|
|
 |
|
  A. Dray Neuropathic pain: emerging treatments Br. J. Anaesth., July 1, 2008; 101(1): 48 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. P. Visanji, A. Orsi, T. H. Johnston, P. A. Howson, K. Dixon, N. Callizot, J. M. Brotchie, and D. D. Rees PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease FASEB J, July 1, 2008; 22(7): 2488 - 2497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. N. Hovland Jr., R. B. Boyd, M. T. Butt, J. A. Engelhardt, M. S. Moxness, M. H. Ma, M. G. Emery, N. B. Ernst, R. P. Reed, J. R. Zeller, et al. Reprint: Six-Month Continuous Intraputamenal Infusion Toxicity Study of Recombinant Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (r-metHuGDNF) in Rhesus Monkeys Toxicol Pathol, December 1, 2007; 35(7): 1013 - 1029. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Dauer Neurotrophic Factors and Parkinson's Disease: The Emergence of a New Player? Sci. Signal., November 6, 2007; 2007(411): pe60 - pe60. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. N. Hovland Jr., R. B. Boyd, M. T. Butt, J. A. Engelhardt, M. S. Moxness, M. H. Ma, M. G. Emery, N. B. Ernst, R. P. Reed, J. R. Zeller, et al. Six-Month Continuous Intraputamenal Infusion Toxicity Study of Recombinant Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (r-metHuGDNF) in Rhesus Monkeys Toxicol Pathol, August 1, 2007; 35(5): 676 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Minguez-Castellanos, F. Escamilla-Sevilla, G. R Hotton, J. J Toledo-Aral, A. Ortega-Moreno, S. Mendez-Ferrer, J. M Martin-Linares, M. J Katati, P. Mir, J. Villadiego, et al. Carotid body autotransplantation in Parkinson disease: a clinical and positron emission tomography study J. Neurol. Neurosurg. Psychiatry, August 1, 2007; 78(8): 825 - 831. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sailer, D. I. Cunic, G. O. Paradiso, C. A. Gunraj, A. Wagle-Shukla, E. Moro, A. M. Lozano, A. E. Lang, and R. Chen Subthalamic nucleus stimulation modulates afferent inhibition in Parkinson disease Neurology, January 30, 2007; 68(5): 356 - 363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Bonuccelli and P. Del Dotto New pharmacologic horizons in the treatment of Parkinson disease. Neurology, October 10, 2006; 67(7 Suppl 2): S30 - S38. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. L. McBride, S. Ramaswamy, M. Gasmi, R. T. Bartus, C. D. Herzog, E. P. Brandon, L. Zhou, M. R. Pitzer, E. M. Berry-Kravis, and J. H. Kordower Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease PNAS, June 13, 2006; 103(24): 9345 - 9350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Dass, C. W. Olanow, and J. H. Kordower Gene transfer of trophic factors and stem cell grafting as treatments for Parkinson's disease Neurology, May 23, 2006; 66(10_suppl_4): S89 - S103. [Abstract] [Full Text]
|
|
|
|
|
|
S.Y.H. Kim, R. G. Holloway, S. Frank, C. A. Beck, C. Zimmerman, R. Wilson, and K. Kieburtz Volunteering for early phase gene transfer research in Parkinson disease Neurology, April 11, 2006; 66(7): 1010 - 1015. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Albers, C. J. Woodbury, A. M. Ritter, B. M. Davis, and H. R. Koerber Glial cell line-derived neurotrophic factor expression in skin alters the mechanical sensitivity of cutaneous nociceptors. J. Neurosci., March 15, 2006; 26(11): 2981 - 2990. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A H V Schapira Present and future drug treatment for Parkinson's disease J. Neurol. Neurosurg. Psychiatry, November 1, 2005; 76(11): 1472 - 1478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Frank, K. Kieburtz, R. Holloway, and S. Y.H. Kim What is the risk of sham surgery in Parkinson disease clinical trials? A review of published reports Neurology, October 11, 2005; 65(7): 1101 - 1103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. -L. Kuan and R. A. Barker New Therapeutic Approaches to Parkinson's Disease Including Neural Transplants Neurorehabil Neural Repair, September 1, 2005; 19(3): 155 - 181. [Abstract] [PDF]
|
|
|
|
 |
|
 C. W. Olanow Double-Blind, Placebo-Controlled Trials for Surgical Interventions in Parkinson Disease Arch Neurol, September 1, 2005; 62(9): 1343 - 1344. [Full Text] [PDF]
|
|
|
|
|
|
S. Y. H. Kim, S. Frank, R. Holloway, C. Zimmerman, R. Wilson, and K. Kieburtz Science and Ethics of Sham Surgery: A Survey of Parkinson Disease Clinical Researchers Arch Neurol, September 1, 2005; 62(9): 1357 - 1360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Villadiego, S. Mendez-Ferrer, T. Valdes-Sanchez, I. Silos-Santiago, I. Farinas, J. Lopez-Barneo, and J. J. Toledo-Aral Selective Glial Cell Line-Derived Neurotrophic Factor Production in Adult Dopaminergic Carotid Body Cells In Situ and after Intrastriatal Transplantation J. Neurosci., April 20, 2005; 25(16): 4091 - 4098. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. van den Bent Prevention of Chemotherapy-Induced Neuropathy: Leukemia Inhibitory Factor Clin. Cancer Res., March 1, 2005; 11(5): 1691 - 1693. [Full Text] [PDF]
|
|
|
|
|
|
A. Eslamboli, B. Georgievska, R. M. Ridley, H. F. Baker, N. Muzyczka, C. Burger, R. J. Mandel, L. Annett, and D. Kirik Continuous Low-Level Glial Cell Line-Derived Neurotrophic Factor Delivery Using Recombinant Adeno-Associated Viral Vectors Provides Neuroprotection and Induces Behavioral Recovery in a Primate Model of Parkinson's Disease J. Neurosci., January 26, 2005; 25(4): 769 - 777. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Maswood, J. Young, E. Tilmont, Z. Zhang, D. M. Gash, G. A. Gerhardt, R. Grondin, G. S. Roth, J. Mattison, M. A. Lane, et al. Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease PNAS, December 28, 2004; 101(52): 18171 - 18176. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. LeWitt Clinical trials of neuroprotection for Parkinson's disease Neurology, October 12, 2004; 63(7_suppl_2): S23 - S31. [Full Text]
|
|
|
|
|
|
N. Kholodilov, O. Yarygina, T. F. Oo, H. Zhang, D. Sulzer, W. Dauer, and R. E. Burke Regulation of the Development of Mesencephalic Dopaminergic Systems by the Selective Expression of Glial Cell Line-Derived Neurotrophic Factor in Their Targets J. Neurosci., March 24, 2004; 24(12): 3136 - 3146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kobori, J. C. Waymire, J. W. Haycock, G. L. Clifton, and P. K. Dash Enhancement of Tyrosine Hydroxylase Phosphorylation and Activity by Glial Cell Line-derived Neurotrophic Factor J. Biol. Chem., January 16, 2004; 279(3): 2182 - 2191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Hamani, J. A. Saint-Cyr, J. Fraser, M. Kaplitt, and A. M. Lozano The subthalamic nucleus in the context of movement disorders Brain, January 1, 2004; 127(1): 4 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mata, J. C. Glorioso, and D. J. Fink Gene Transfer to the Nervous System: Prospects for Novel Treatments Directed at Diseases of the Aging Nervous System J. Gerontol. A Biol. Sci. Med. Sci., December 1, 2003; 58(12): M1111 - 1118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. W. Shults Treatments of Parkinson Disease: Circa 2003 Arch Neurol, December 1, 2003; 60(12): 1680 - 1684. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
